Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

References

• Ferrari A, Sultan I, Huang TT., et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011;57(6):943–949. doi:10.1002/pbc.23252
   PubMed Web of Science ®Google Scholar
• Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med. 2014;3:1404–1415. doi:10.1002/cam4.288
   PubMed Web of Science ®Google Scholar
• WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol.3). ISBN 978-92-832-4502-5. https://publications.iarc.fr/588. Accessed September 13, 2022.
   Google Scholar
• Pfister SM, Reyes-Múgica M, Chan JKC, et al. A summary of the inaugural WHO Classification of Pediatric Tumors: transitioning from the optical into the molecular era. Cancer Discov. 2022;12(2):331–355. doi:10.1158/2159-8290.CD-21-1094
   PubMed Web of Science ®Google Scholar
• van der Graaf WTA, Orbach D. Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. Lancet Oncol. 2017;18:e166–e175. doi:10.1016/S1470-2045(17)30099-2
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bleyer A, Patel S, et al. The challenge of the management of adolescents and young adults with soft tissue sarcomas. Pediatr Blood Cancer. 2018;65(7):e27013. doi:10.1002/pbc.27013
   PubMed Web of Science ®Google Scholar
• Ferrari A, Spunt SL, Sparber-Sauer M, et al. Controversies and challenges in the management of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Lancet Child Adolesc Health. 2022;6(4):221–223. doi:10.1016/S2352-4642(22)00036-0
   PubMedGoogle Scholar
• Gutierrez JC, Perez EA, Moffat FL, et al. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg. 2007;245(6):952–958. doi:10.1097/01.sla.0000250438.04393.a8
   PubMed Web of Science ®Google Scholar
• Collignon C, Carton M, Brisse HJ, et al. Soft tissue sarcoma in children, adolescents and young adults: outcomes according to compliance with international initial care guidelines. Eur J Surg Oncol. 2020;46(7):1277–1286. doi:10.1016/j.ejso.2019.11.518
   PubMed Web of Science ®Google Scholar
• Ferrari A, Orbach D, Sparber-Sauer M, et al. The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium. Eur J Cancer. 2022;169:10–19. doi:10.1016/j.ejca.2022.03.028
   PubMed Web of Science ®Google Scholar
• Spunt SL, Poquette CA, Hurt YS, et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children’s Research Hospital. J Clin Oncol. 1999;17:3697e705. doi:10.1200/JCO.1999.17.12.3697
   Web of Science ®Google Scholar
• Spunt SL, Hill DA, Motosue AM, et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Clin Oncol. 2002;20:3225e35. doi:10.1200/JCO.2002.06.066
   Web of Science ®Google Scholar
• Ferrari A, Casanova M, Collini P, et al. Adult-type soft tissue sarcomas in pediatric age patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol. 2005;23:4021e30. doi:10.1200/JCO.2005.02.053
   Web of Science ®Google Scholar
• Ferrari A, Miceli R, Casanova M, et al. Adult-type soft tissue sarcomas in pediatric age: a nomogram-based prognostic comparison with adult sarcomas. Eur J Canc. 2007;43:2691e7. doi:10.1016/j.ejca.2007.09.012
   Web of Science ®Google Scholar
• Pratt CB, Maurer HM, Gieser P, et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. Med Pediatr Oncol. 1998;30:201–209. doi:10.1002/(SICI)1096-911X(199804)30:4<201::AID-MPO1>3.0.CO;2-K
   PubMedGoogle Scholar
• Pratt CB, Pappo AS, Gieser P, et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol. 1999;17:1219.
   PubMed Web of Science ®Google Scholar
• Pappo AS, Rao BN, Jenkins JJ, et al. Metastatic nonrhabdomyosarcomatous soft-tissue sarcomas in children and adolescents: the St. Med Pediatr Oncol. 1999;33:76–82. doi:10.1002/(SICI)1096-911X(199908)33:2<76::AID-MPO3>3.0.CO;2-B
   PubMedGoogle Scholar
• Pappo AS, Devidas M, Jenkins J, et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol. 2005;23:4031–4038. doi:10.1200/JCO.2005.03.209
   PubMed Web of Science ®Google Scholar
• Ferrari A, van Noesel MM, Brennan B, et al. Pediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European pediatric Soft tissue sarcoma Study Group (EpSSG). Lancet Child Adol Health. 2021;5(8):546–558. doi:10.1016/S2352-4642(21)00159-0
   Web of Science ®Google Scholar
• Spunt SL, Million L, Chi -Y-Y, et al. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children’s Oncology Group prospective study. Lancet Oncol. 2020;21(1):145–161. doi:10.1016/S1470-2045(19)30672-2
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Brennan B, et al. Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol. 2015;26:567–572. doi:10.1093/annonc/mdu562
   PubMed Web of Science ®Google Scholar
• Orbach D, Brennan B, De Paoli A, et al. Conservative strategy in infantile fibrosarcoma is possible: the European pediatric Soft tissue sarcoma Study Group experience. Eur J Cancer. 2016;57:1–9. doi:10.1016/j.ejca.2015.12.028
   PubMed Web of Science ®Google Scholar
• Brennan B, De Salvo GL, Orbach D, et al. Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005. Eur J Cancer. 2016;60:69–82. doi:10.1016/j.ejca.2016.02.027
   PubMed Web of Science ®Google Scholar
• Ferrari A, Chi Y, De Salvo GL, et al. Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: a joint analysis from the European paediatric Soft tissue sarcoma Study Group and the Children’s Oncology Group. Eur J Cancer. 2017;78(1–6). doi:10.1016/j.ejca.2017.03.003.
   PubMed Web of Science ®Google Scholar
• Orbach D, Brennan B, Bisogno G, et al. Desmoid tumors in children: the experience of the European pediatric Soft tissue sarcoma Study Group (EpSSG) – NRSTS 05 study – an international prospective case series. Lancet Child Adolescent Health. 2017;1:284–292. doi:10.1016/S2352-4642(17)30045-7
   PubMedGoogle Scholar
• Brennan B, Zanetti I, Orbach D, et al. Alveolar soft part sarcoma in children and adolescents: the European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005). Pediatr Blood Cancer. 2018;65(4):e26942. doi:10.1002/pbc.26942
   Web of Science ®Google Scholar
• Orbach D, Mosseri V, Pissaloux D, et al. Genomic complexity in pediatric synovial sarcoma (SYNOBIO study): the European Pediatric Soft Tissue Sarcoma Group (EpSSG NRSTS 2005) experience. Cancer Med. 2018;7(4):1384–1393. doi:10.1002/cam4.1415
   PubMed Web of Science ®Google Scholar
• Spunt SL, Francotte N, De Salvo GL, et al. Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children’s Oncology Group (COG) and the European paediatric soft tissue Sarcoma Study Group (EpSSG) prospective clinical trials. Eur J Cancer. 2019;112:98–106. doi:10.1016/j.ejca.2019.02.001
   PubMed Web of Science ®Google Scholar
• van Noesel MM, Orbach D, Brennan B, et al. Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: an analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. Pediatr Blood Cancer. 2019;66(10):e27833. doi:10.1002/pbc.27833
   PubMed Web of Science ®Google Scholar
• Casanova M, Brennan B, Alaggio R, et al. Inflammatory myofibroblastic tumor: the experience of the European paediatric Soft Tissue Sarcoma Study Group (EpSSG). Eur J Cancer. 2020;127:123–129. doi:10.1016/j.ejca.2019.12.021
   PubMed Web of Science ®Google Scholar
• Brennan B, Zanetti I, De Salvo GL, et al. Dermatofibrosarcoma protuberans in children and adolescents: the European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Pediatr Blood Cancer. 2020;67(10):e28351. doi:10.1002/pbc.28351
   PubMed Web of Science ®Google Scholar
• Ferrari A, Merks JHM, Chisholm JC, et al. Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. Eur J Cancer. 2020;130:72–80. doi:10.1016/j.ejca.2020.01.029
   PubMed Web of Science ®Google Scholar
• Casanova M, Ferrari A, Bisogno G, et al. Alveolar soft part sarcoma in children and adolescents: a report from the Soft-Tissue Sarcoma Italian Cooperative Group. Ann Oncol. 2000;11:1445–1449. doi:10.1023/A:1026579623136
   PubMed Web of Science ®Google Scholar
• Orbach D, Brennan B, Casanova M, et al. Paediatric and adolescent alveolar soft part sarcoma: a joint series from European cooperative groups. Pediatr Blood Cancer. 2013;60:1826–1832. doi:10.1002/pbc.24683
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M, Bisogno G, et al. Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group. Cancer. 2002;94(12):3269–3276. doi:10.1002/cncr.10597
   PubMed Web of Science ®Google Scholar
• Kelleher FC, Viterbo A. Histologic and genetic advances in refining the diagnosis of ”undifferentiated pleomorphic sarcoma”. Cancers. 2013;5(1):218–233. doi:10.3390/cancers5010218
   PubMedGoogle Scholar
• Cohen-Gogo S, Cellier C, Coindre JM, et al. Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: a clinical, radiological and pathological retrospective study from the Societe Francaise des Cancers de L’Enfant. Pediatr Blood Cancer. 2014;61(12):2191–2198. doi:10.1002/pbc.25210
   PubMed Web of Science ®Google Scholar
• Grier HE. Soft tissue sarcoma: apples, oranges, and passion fruit. J Clin Oncol. 1999;17(12):3695–3696. doi:10.1200/JCO.1999.17.12.3695
   PubMed Web of Science ®Google Scholar
• Ferrari A, Miceli R, Rey A, et al. Non-metastatic unresected pediatric nonrhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Canc. 2011;47:724e31. doi:10.1016/j.ejca.2010.11.013
   Web of Science ®Google Scholar
• Milgrom SA, Million L, Mandeville H, et al. Non-rhabdomyosarcoma soft-tissue sarcoma. Pediatr Blood Cancer. 2021;68(Suppl 2):e28279. doi:10.1002/pbc.28279
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–315. doi:10.1097/00000658-198209000-00009
   PubMed Web of Science ®Google Scholar
• Rao AD, Chen Q, Million L, et al. Preoperative intensity modulated radiation therapy compared to three-dimensional conformal radiation therapy for high-grade extremity sarcomas in children: analysis of the Children’s Oncology Group Study ARST0332. Int J Radiat Oncol Biol Phys. 2019;103(1):38–44. doi:10.1016/j.ijrobp.2018.09.005
   PubMed Web of Science ®Google Scholar
• FitzGerald TJ, Followill D, Laurie F, et al. Quality assurance in radiation oncology. Pediatr Blood Cancer. 2021;68(Suppl 2):e28609. doi:10.1002/pbc.28609
   PubMed Web of Science ®Google Scholar
• Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238–1247. doi:10.1200/JCO.2001.19.5.1238
   PubMed Web of Science ®Google Scholar
• Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30:850–856. doi:10.1200/JCO.2011.37.7218
   PubMed Web of Science ®Google Scholar
• Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020;38(19):2178–2186. doi:10.1200/JCO.19.03289
   PubMed Web of Science ®Google Scholar
• Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647–1654. doi:10.1016/S0140-6736(97)08165-8
   PubMed Web of Science ®Google Scholar
• Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573–581. doi:10.1002/cncr.23592
   PubMed Web of Science ®Google Scholar
• Pasquali S, Pizzamiglio S. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019;109:51–60. doi:10.1016/j.ejca.2018.12.009
   PubMed Web of Science ®Google Scholar
• Ferrari A, Brecht IB, Koscielniak E, et al. The role of adjuvant chemotherapy in children and adolescents with surgically-resected high-risk adult-type soft tissue sarcomas. Ped Blood Cancer. 2005;45(2):128–134. doi:10.1002/pbc.20376
   PubMed Web of Science ®Google Scholar
• Sultan I, Rodriguez-Galindo C, Saab R, et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115(15):3537–3547. doi:10.1002/cncr.24424
   PubMed Web of Science ®Google Scholar
• Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003;21:1602–1611. doi:10.1200/JCO.2003.07.008
   PubMed Web of Science ®Google Scholar
• Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101:627–634. doi:10.1002/cncr.20386
   PubMed Web of Science ®Google Scholar
• Brecht IB, Ferrari A, Int-Veen C, et al. Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: discussion on the role of adjuvant therapies. Pediatr Blood Cancer. 2006;46:11–17. doi:10.1002/pbc.20502
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bisogno G, Alaggio G, et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer. 2008;44:1202–1209. doi:10.1016/j.ejca.2008.03.016
   PubMed Web of Science ®Google Scholar
• Brennan B, Stevens M, Kelsey A, et al. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children’s Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer. 2010;55:85–90. doi:10.1002/pbc.22453
   PubMed Web of Science ®Google Scholar
• Orbach D, Dowell HM, Rey A, et al. Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOP-MMT) working group. Pediatr Blood Cancer. 2011;57(7):1130–1136. doi:10.1002/pbc.23138
   PubMed Web of Science ®Google Scholar
• Venkatramani R, Xue W, Randall RL, et al. Synovial Sarcoma in Children, Adolescents, and Young Adults: a Report From the Children’s Oncology Group ARST0332 Study. J Clin Oncol. 2021;39(35):3927–3937. doi:10.1200/JCO.21.01628
   PubMed Web of Science ®Google Scholar
• Antman K, Crowley J, Balcerzak SP, et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276–1285. doi:10.1200/JCO.1993.11.7.1276
   PubMed Web of Science ®Google Scholar
• Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled Phase 3 trial. Lancet Oncol. 2014;15(4):415–423. doi:10.1016/S1470-2045(14)70063-4
   PubMed Web of Science ®Google Scholar
• Chiaravalli S, Bergamaschi L, Livellara V, et al. Adult-type non-rhabdomyosarcoma soft tissue sarcomas in pediatric age: salvage rates and prognostic factors after relapse. Eur J Cancer. 2022;169:179–187. doi:10.1016/j.ejca.2022.03.037
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Dall’Igna P, et al. Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. Eur J Cancer. 2012;48:3448–3455. doi:10.1016/j.ejca.2012.06.017
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13(7):1600–1608. doi:10.1200/JCO.1995.13.7.1600
   PubMed Web of Science ®Google Scholar
• Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000;36(1):61–67. doi:10.1016/S0959-8049(99)00240-3
   PubMed Web of Science ®Google Scholar
• Palumbo R, Palmeri S, Antimi M, et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol. 1997;8(11):1159–1162. doi:10.1023/A:1008279426654
   PubMed Web of Science ®Google Scholar
• Meazza C, Casanova M, Luksch R, et al. Prolonged 14-Day Continuous Infusion of High-Dose Ifosfamide With an External Portable Pump: feasibility and Efficacy in Refractory Pediatric Sarcoma. Pediatr Blood Cancer. 2010;55:617–620. doi:10.1002/pbc.22596
   PubMed Web of Science ®Google Scholar
• Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755–2763. doi:10.1200/JCO.2006.10.4117
   PubMed Web of Science ®Google Scholar
• Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007;109(9):1863–1869. doi:10.1002/cncr.22609
   PubMed Web of Science ®Google Scholar
• Fata F, O’Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034–2037. doi:10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P
   PubMed Web of Science ®Google Scholar
• Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629–1637. doi:10.1016/S0140-6736(15)01283-0
   PubMed Web of Science ®Google Scholar
• Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8(7):595–602. doi:10.1016/S1470-2045(07)70175-4
   PubMed Web of Science ®Google Scholar
• Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013;24:1703–1709. doi:10.1093/annonc/mds659
   PubMed Web of Science ®Google Scholar
• Frezza AM, Whelan JS, Dileo P. Trabectedin for desmoplastic small round cell tumours: a possible treatment option? Clin Sarcoma Res. 2014;4:3. doi:10.1186/2045-3329-4-3
   PubMedGoogle Scholar
• Baldi GG, Orbach D, Bertulli R, et al. Standard treatment and emerging drugs for managing synovial sarcoma: adult’s and pediatric oncologist perspective. Expert Opin Emerg Drugs. 2019;24(1):43–53. doi:10.1080/14728214.2019.1591367
   PubMed Web of Science ®Google Scholar
• van der Graaf WTA, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo controlled phase 3 trial. Lancet. 2012;379:1879–1886. doi:10.1016/S0140-6736(12)60651-5
   PubMed Web of Science ®Google Scholar
• Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Oncol. 2016;17(12):1732–1742. doi:10.1016/S1470-2045(16)30507-1
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Attia S, Blay JY, et al. Identification of response stratification factors from pooled efficacy analyses afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase and phase 2 trials. J Clin Oncol. 2022;40(16):11562. doi:10.1200/JCO.2022.40.16_suppl.11562
   Web of Science ®Google Scholar
• Bisogno G, Ferrari A, Alaggio R, et al. Treatment options for alveolar soft part sarcoma in paediatric patients. Exp Opin Orphan Drugs. 2014;2(6):579–589. doi:10.1517/21678707.2014.896191
   Web of Science ®Google Scholar
• Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22:1682–1690. doi:10.1093/annonc/mdq644
   PubMed Web of Science ®Google Scholar
• Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013;31:2296–2302. doi:10.1200/JCO.2012.47.4288
   PubMed Web of Science ®Google Scholar
• Kerrison WGJ, Lee ATJ, Thway K, et al. Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas. Biomedicines. 2022;10(3):573. doi:10.3390/biomedicines10030573
   PubMed Web of Science ®Google Scholar
• Shi Y, Cai Q, Jiang Y, et al. Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: a Phase II, Single-arm Study. Clin Cancer Res. 2020;26:6445–6452. doi:10.1158/1078-0432.CCR-20-2819
   PubMed Web of Science ®Google Scholar
• Naqash AR, Coyne GHO, Moore N, et al. Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS). J Clin Oncol. 2021;39:11519. doi:10.1200/JCO.2021.39.15_suppl.11519
   Web of Science ®Google Scholar
• Blay JY, Penel N, Ray-Coquard IL, et al. High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: the French AcSé pembrolizumab study from Unicancer. J Clin Oncol. 2021;39:11520. doi:10.1200/JCO.2021.39.15_suppl.11520
   Web of Science ®Google Scholar
• Jones AL, Joon A, Haydu LE, et al. Outcomes of melanoma soft parts/clear cell sarcoma (MSP/CCS) patients (pts) with immune and targeted therapies. J Clin Oncol. 2019;37:e21046. doi:10.1200/JCO.2019.37.15_suppl.e21046
   Web of Science ®Google Scholar
• Krewer J, Rolle U, Koscielniak E, et al. Dermatofibrosarcoma protuberans in children and adolescents: primary and relapsed disease - experience of the Cooperative Weichteilsarkomstudiengruppe (CWS). J Surg Oncol. 2020;122(2):263–272. doi:10.1002/jso.25943
   PubMed Web of Science ®Google Scholar
• McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23(4):866–873. doi:10.1200/JCO.2005.07.088
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Klimczak A, Lugowska I, et al. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. Eur J Surg Oncol. 2017;43:1134–1141. doi:10.1016/j.ejso.2017.03.011
   PubMed Web of Science ®Google Scholar
• Navarrete-Dechent C, Mori S, Barker CA, et al. Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review. JAMA Dermatol. 2019;155(3):361–369. doi:10.1001/jamadermatol.2018.4940
   PubMed Web of Science ®Google Scholar
• Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122:2983e8. doi:10.1172/JCI64400
   Web of Science ®Google Scholar
• Enault M, Minard-Colin V, Corradini N, et al. Extracranial rhabdoid tumours: results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations. Eur J Cancer. 2021;161:64–78. doi:10.1016/j.ejca.2021.10.025
   PubMed Web of Science ®Google Scholar
• Italiano A, Soria J-C, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, Phase 1 study. Lancet Oncol. 2018;19:649–659. doi:10.1016/S1470-2045(18)30145-1
   PubMed Web of Science ®Google Scholar
• Kerl K, Ries D, Unland R, et al. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer;2013. 13. doi:10.1186/1471-2407-13-13
   PubMed Web of Science ®Google Scholar
• Geoerger B, Zwaan CM, Marshall LV, et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Lancet Oncol. 2020;21:134–144. doi:10.1016/S1470-2045(19)30693-X
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21:121–133. doi:10.1016/S1470-2045(19)30671-0
   PubMed Web of Science ®Google Scholar
• Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol. 1996;14:1526–1531. doi:10.1200/JCO.1996.14.5.1526
   PubMed Web of Science ®Google Scholar
• Scheer M, Vokuhl C, Blank B, et al. Desmoplastic small round cell tumors: multimodality treatment and new risk factors. Cancer Med. 2019;8:527–542. doi:10.1002/cam4.1940
   PubMed Web of Science ®Google Scholar
• Bisogno G, Ferrari A, Rosolen A, et al. Sequential intensified chemotherapy with stem cell rescue for children and adolescents with desmoplastic small round-cell tumor. Bone Marrow Transplant. 2010;45(5):907–911. doi:10.1038/bmt.2009.248
   PubMed Web of Science ®Google Scholar
• Hayes-Jordan A, Green HL, Lin H, et al. Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor. Ann Surg Oncol. 2014;21:220–224. doi:10.1245/s10434-013-3269-y
   PubMed Web of Science ®Google Scholar
• Desai NB, Stein NF, LaQuaglia MP, et al. Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAP-RT) experience. Int J Radiat Oncol Biol Phys. 2013;85(1):e67–e72. doi:10.1016/j.ijrobp.2012.09.005
   PubMed Web of Science ®Google Scholar
• Honoré C, Delhorme JB, Nassif E, et al. Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. Surg Oncol. 2019;29:107–112. doi:10.1016/j.suronc.2019.04.002
   PubMed Web of Science ®Google Scholar
• Honoré C, Atallah V, Mir O, et al. Abdominal desmoplastic small round cell tumor without extra peritoneal metastases: is there a benefit for HIPEC after macroscopically complete cytoreductive surgery? PLoS One. 2017;12(2):e0171639. doi:10.1371/journal.pone.0171639
   PubMed Web of Science ®Google Scholar
• Atallah V, Honore C, Orbach D, et al. Role of adjuvant radiation therapy after surgery for abdominal desmoplastic small round cell tumors. Int J Radiat Oncol Biol Phys. 2016;95(4):1244–1253. doi:10.1016/j.ijrobp.2016.02.046
   PubMed Web of Science ®Google Scholar
• Olivier-Gougenheim L, Orbach D, Atallah V, et al. Desmoplastic small round cell tumors with EWS-WT1 transcript expression: should we consider children and adult patients differently? J Pediatr Hematol Oncol. 2022;44(3):e637–e642. doi:10.1097/MPH.0000000000002252
   PubMed Web of Science ®Google Scholar
• Liu KX, Collins NB, Greenzang KA, et al. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020;67(10):e28559. doi:10.1002/pbc.28559
   PubMed Web of Science ®Google Scholar
• Italiano A, Kind M, Cioffi A, et al. Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. Target Oncol. 2013;8(3):211–213. doi:10.1007/s11523-012-0251-8
   PubMed Web of Science ®Google Scholar
• Schoot RA, Chisholm JC, Casanova M, et al. Metastatic rhabdomyosarcoma: results of the European paediatric Soft tissue sarcoma Study Group MTS 2008 study and pooled analysis with the concurrent BERNIE study. J Clin Oncol. 2022. doi:10.1200/JCO.21.02981
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bergamaschi L, Chiaravalli S, et al. Multiagent chemotherapy including IrIVA regimen and maintenance therapy in the treatment of desmoplastic small round cell tumor. Tumori. 2022;108(1):93–97. doi:10.1177/0300891621995250
   PubMed Web of Science ®Google Scholar
• Ferrari A, Grosso F, Stacchiotti S, et al. Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor. Ped Blood Cancer. 2007;49(6):864–866. doi:10.1002/pbc.20682
   PubMed Web of Science ®Google Scholar
• Kao YC, Owosho AA, Sung YS, et al. BCOR-CCNB3 Fusion positive sarcomas: a clinicopathologic and molecular analysis of 36 cases with comparison to morphologic spectrum and clinical behavior of other round cell sarcomas. Am J Surg Pathol. 2018;42(5):604–615. doi:10.1097/PAS.0000000000000965
   PubMed Web of Science ®Google Scholar
• Cohen-Gogo S, Cellier C, Coindre JM, et al. Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: a clinical, radiological and pathological retrospective study from the Société Française des Cancers de L’Enfant. Pediatr Blood Cancer. 2014;61(12):2191–2198.
   PubMed Web of Science ®Google Scholar
• Brčić I, Brodowicz T, Cerroni L, et al. round cell sarcomas with CIC-DUX4 gene fusion: expanding the clinical spectrum. Pathology. 2020;52(2):236–242. doi:10.1016/j.pathol.2019.09.015
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Owosho AA, Zhang L, et al. Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases. Am J Surg Pathol. 2017;41(7):941–949. doi:10.1097/PAS.0000000000000846
   PubMed Web of Science ®Google Scholar
• Meazza C, Bisogno G, Gronchi A, et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer. 2010;116(1):233–240. doi:10.1002/cncr.24679
   PubMed Web of Science ®Google Scholar
• Sparber-Sauer M, Seitz G, von Kalle T, et al. Systemic therapy of aggressive fibromatosis in children and adolescents: report of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer. 2018;65(5):e26943. doi:10.1002/pbc.26943
   PubMed Web of Science ®Google Scholar
• Desmoid Tumor Working Group. The management of desmoid tumors: a joint global consensus-based guideline approach for adult and pediatric patients. Eur J Cancer. 2020;127:96–107. doi:10.1016/j.ejca.2019.11.013
   PubMed Web of Science ®Google Scholar
• Sparber-Sauer M, Orbach D, Navid F, et al. Rationale for the use of tyrosine kinase inhibitors in the treatment of pediatric desmoid-type fibromatosis. Br J Cancer. 2021;124(10):1637–1646. doi:10.1038/s41416-021-01320-1
   PubMed Web of Science ®Google Scholar
• Vora BMK, Munk PL, Somasundaram N, et al. Cryotherapy in extra-abdominal desmoid tumors: a systematic review and meta-analysis. PLoS One. 2021;16(12):e0261657. doi:10.1371/journal.pone.0261657
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015;39(7):957e67. doi:10.1097/PAS.0000000000000404
   Web of Science ®Google Scholar
• Kube S, Vokuhl C, Dantonello T, et al. Inflammatory myofibroblastic tumors - A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2018;65(6):e27012. doi:10.1002/pbc.27012
   PubMed Web of Science ®Google Scholar
• Pire A, Orbach D, Galmiche L, et al. Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents. Pediatr Blood Cancer. 2022;69(5):e29460. doi:10.1002/pbc.29460
   PubMed Web of Science ®Google Scholar
• Butrynski JE, D’Adamo DR, Hornick JL, et al. Crizotinib in ALK rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363:1727–1733. doi:10.1056/NEJMoa1007056
   PubMed Web of Science ®Google Scholar
• Mosse´ YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group Study. J Clin Oncol. 2017;35:3215e21. doi:10.1200/JCO.2017.73.4830
   Web of Science ®Google Scholar
• Mahajan P, Casanova M, Ferrari A, et al. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Probl Cancer. 2021;45(4):100768. doi:10.1016/j.currproblcancer.2021.100768
   PubMed Web of Science ®Google Scholar
• Orbach D, Sparber-Sauer M, Laetsch TW, et al. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: international consensus and remaining controversies. Eur J Cancer. 2020;137:183–192. doi:10.1016/j.ejca.2020.06.028
   PubMed Web of Science ®Google Scholar
• Orbach D, Rey A, Cecchetto G, et al. Infantile fibrosarcoma: place of chemotherapy and treatment proposals based on the European experience. J Clin Oncol. 2010;28(2):318–323. doi:10.1200/JCO.2009.21.9972
   PubMed Web of Science ®Google Scholar
• Sparber-Sauer M, Vokuhl C, Seitz G, et al. The impact of local control in the treatment of children with advanced infantile and adult-type fibrosarcoma: experience of the cooperative weichteilsarkom studiengruppe (CWS). J Pediatr Surg. 2020;55(9):1740–1747. doi:10.1016/j.jpedsurg.2019.10.051
   PubMed Web of Science ®Google Scholar
• Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumors harbouring NTRK gene fusions: a multicentre, open-label, phase 1 study. Lancet Oncol. 2018;19(5):705–714. doi:10.1016/S1470-2045(18)30119-0
   PubMed Web of Science ®Google Scholar
• Hingorani P, Janeway K, Crompton BD, et al. Current state of pediatric sarcoma biology and opportunities for future discovery: a report from the sarcoma translational research workshop. Cancer Genet. 2016;209(5):182–194. doi:10.1016/j.cancergen.2016.03.004
   PubMed Web of Science ®Google Scholar
• Koelsche C, Schrimpf D, Stichel D, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12(1):498. doi:10.1038/s41467-020-20603-4
   PubMed Web of Science ®Google Scholar
• Wei J, Liu X, Li T, et al. The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids. J Cancer. 2020;11(18):5293–5308. doi:10.7150/jca.42816
   PubMed Web of Science ®Google Scholar
• Colella G, Fazioli F, Gallo M, et al. Sarcoma spheroids and organoids - promising tools in the era of personalized medicine. Int J Mol Sci. 2018;19(2):615. doi:10.3390/ijms19020615
   PubMed Web of Science ®Google Scholar
• van Tilburg CM, Pfaff E, Pajtler KW, et al. The Pediatric Precision Oncology INFORM Registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov. 2021;11(11):2764–2779. doi:10.1158/2159-8290.CD-21-0094
   PubMed Web of Science ®Google Scholar
• Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013;31:608–615. doi:10.1200/JCO.2012.46.0147
   PubMed Web of Science ®Google Scholar
• Weiss AR, Chen YL, Scharschmidt TJ, et al. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(8):1110–1122. doi:10.1016/S1470-2045(20)30325-9
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Bisogno G, Koscielniak E. Introducing INSTRuCT: an international effort to promote cooperation and data sharing. Pediatr Blood Cancer. 2020;e28701. doi:10.1002/pbc.28701
   PubMed Web of Science ®Google Scholar